Prosecution Insights
Last updated: July 17, 2026

Giordano Law LLC

8 pending office actions • 3 clients • 8 examiners • 6 art units • 0 of 8 (0%) have an AI response strategy ready • 8 patents granted in the last 365 days

Quality Metrics (n=132 apps, methodology: how we score firms)

79.1%
Allowance Rate
n=132
+0.58σ
Allowance Rate (norm)
n=132
3.1
OAs to Allowance
n=72
-0.35σ
OAs to Allow (norm)
n=72
794 days
Time to Allowance
n=72
+29.2pp
Interview Lift
n=132
29.7%
RCE Rate
n=132
2.0%
Appeal Rate
n=132

Rejection Performance (% of received rejections ultimately overcome)

§101 Overcome
n=4 (min 20)
§102 Overcome
n=8 (min 20)
62.8%
§103 Overcome
n=51
§112 Overcome
n=12 (min 20)

Specialization & Scale

H04M, A61K, H04W
Top CPC Subclasses
39%
Top-3 CPC Share
n=132
0
Practitioners
n=132
Apps / Practitioner
n=132 (min 20)

Portfolio Summary

8
Total Pending OAs
4
Non-Final OAs
4
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

2
Overdue
0
Due this week
1
Due this month
1
Due in next 60 days
0
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (2)Due ≤ 30 days (1)Due ≤ 60 days (1)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
7
Medium (88%)
1
Easy (12%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only7 (88%)
Double-patenting only1 (12%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

6
Life Sciences
75% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
2
Mechanical / Eng
25% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

80 h
Manual time on pending OAs
16 h
Time saved (low, 20%)
28 h
Time saved (mid, 35%)
0.7 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
NEAL, ALLISON MICHELLE 1 19.7% +27.1%
HAN, ROBIN 1 32.4% +61.4%
NGUYEN, JOHN P 1 44.3% +41.3%
KASSA, TIGABU 1 36.5% +28.2%
KOSTURKO, GEORGE W 1 54.7% +48.6%
GOTFREDSON, GAREN 1 39.7% +29.0%
KWON, JOHN SEUNGJAI 1 44.6% +18.9%
HUTTER, GILLIAN A 1 53.8% +46.6%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18920156 AUTOMATIC AFTER CALL SURVEY AND CAMPAIGN-BASED CUSTOMER FEEDBACK COLLECTION PLATFORM NEAL, ALLISON MICHELLE

Interview Candidates (8)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.

App #TitleExaminerDue in
17802054 PHARMACEUTICAL COMPOSITION COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND GOTFREDSON, GAREN 30d overdue
17429732 PHARMACEUTICAL COMPOSITION COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND HUTTER, GILLIAN A 25d overdue
18269421 PHARMACEUTICAL COMPOSITION COMPRISING TEGOPRAZAN AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS NGUYEN, JOHN P 28d
18691840 Intrauterine Contraceptive Device HAN, ROBIN 56d
18920156 AUTOMATIC AFTER CALL SURVEY AND CAMPAIGN-BASED CUSTOMER FEEDBACK COLLECTION PLATFORM NEAL, ALLISON MICHELLE
18032749 ORALLY DISINTEGRATING TABLET COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND AND PREPARATION METHOD THEREOF KASSA, TIGABU
17918386 PHARMACEUTICAL COMPOSITION COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND KOSTURKO, GEORGE W
17802078 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION KWON, JOHN SEUNGJAI

Client Portfolio (3 clients)

Client (Assignee)Pending OAs
Kolmar Korea 6
Onepin, Inc. 1
Sebela Vlc Limited 1

Top Art Units

Art UnitApps
16193
36251
37861
16211
16151
16251

Pending Office Actions

App #TitleClientExaminerArt UnitStatutesStatusDue inAIFiled
18920156 AUTOMATIC AFTER CALL SURVEY AND CAMPAIGN-BASED CUSTOMER FEEDBACK COLLECTION PLATFORM Onepin, Inc. NEAL, ALLISON MICHELLE 3625 DP Non-Final OA Pending Oct 18, 2024
18691840 Intrauterine Contraceptive Device Sebela Vlc Limited HAN, ROBIN 3786 §103 Final Rejection 56d Pending Mar 13, 2024
18269421 PHARMACEUTICAL COMPOSITION COMPRISING TEGOPRAZAN AND NON-STEROIDAL ANTI-INFLAMMATORY DRUGS Hk Inno.N Corporation NGUYEN, JOHN P 1619 §103 Non-Final OA 28d Pending Jun 23, 2023
18032749 ORALLY DISINTEGRATING TABLET COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND AND PREPARATION METHOD THEREOF Hk Inno.N Corporation KASSA, TIGABU 1619 §103 Final Rejection Pending Apr 19, 2023
17918386 PHARMACEUTICAL COMPOSITION COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND Hk Inno.N Corporation KOSTURKO, GEORGE W 1621 §103 Final Rejection Pending Mar 27, 2023
17802054 PHARMACEUTICAL COMPOSITION COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND Hk Inno.N Corporation GOTFREDSON, GAREN 1619 §103 Final Rejection 30d overdue Pending Aug 24, 2022
17802078 PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION Hk Inno. N Corporation KWON, JOHN SEUNGJAI 1615 §103 Non-Final OA Pending Aug 24, 2022
17429732 PHARMACEUTICAL COMPOSITION COMPRISING BENZIMIDAZOLE DERIVATIVE COMPOUND Hk Inno.N Corporation HUTTER, GILLIAN A 1625 §103 Non-Final OA 25d overdue Pending Aug 10, 2021

Managing Giordano Law LLC's Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month